Wegener ||| S:0 E:7 ||| NNP
's  ||| S:7 E:10 ||| POS
granulomatosis  ||| S:10 E:25 ||| FW
occurring  ||| S:25 E:35 ||| FW
de  ||| S:35 E:38 ||| FW
novo  ||| S:38 E:43 ||| FW
during  ||| S:43 E:50 ||| FW
pregnancy  ||| S:50 E:60 ||| FW
Wegener ||| S:60 E:67 ||| NNP
's  ||| S:67 E:70 ||| POS
granulomatosis  ||| S:70 E:85 ||| NN
( ||| S:85 E:86 ||| -LRB-
WG ||| S:86 E:88 ||| NNP
)  ||| S:88 E:90 ||| -RRB-
is  ||| S:90 E:93 ||| VBZ
rarely  ||| S:93 E:100 ||| RB
diagnosed  ||| S:100 E:110 ||| VBN
during  ||| S:110 E:117 ||| IN
the  ||| S:117 E:121 ||| DT
reproductive  ||| S:121 E:134 ||| JJ
years  ||| S:134 E:140 ||| NNS
and  ||| S:140 E:144 ||| CC
uncommonly  ||| S:144 E:155 ||| JJ
manifests  ||| S:155 E:165 ||| NN
for  ||| S:165 E:169 ||| IN
the  ||| S:169 E:173 ||| DT
first  ||| S:173 E:179 ||| JJ
time  ||| S:179 E:184 ||| NN
during  ||| S:184 E:191 ||| IN
pregnancy ||| S:191 E:200 ||| NN
.  ||| S:200 E:202 ||| .
We  ||| S:202 E:205 ||| PRP
report  ||| S:205 E:212 ||| VBP
a  ||| S:212 E:214 ||| DT
case  ||| S:214 E:219 ||| NN
of  ||| S:219 E:222 ||| IN
de  ||| S:222 E:225 ||| FW
novo  ||| S:225 E:230 ||| FW
WG  ||| S:230 E:233 ||| FW
presenting  ||| S:233 E:244 ||| FW
at  ||| S:244 E:247 ||| IN
30  ||| S:247 E:250 ||| CD
weeks  ||| S:250 E:256 ||| NNS
gestation  ||| S:256 E:266 ||| VBN
with  ||| S:266 E:271 ||| IN
classical  ||| S:271 E:281 ||| JJ
symptoms  ||| S:281 E:290 ||| NNS
of  ||| S:290 E:293 ||| IN
WG  ||| S:293 E:296 ||| NNP
( ||| S:296 E:297 ||| -LRB-
ENT ||| S:297 E:300 ||| NNP
,  ||| S:300 E:302 ||| ,
pulmonary ||| S:302 E:311 ||| CD
) ||| S:311 E:312 ||| -RRB-
.  ||| S:312 E:314 ||| .
The  ||| S:314 E:318 ||| DT
diagnosis  ||| S:318 E:328 ||| NN
was  ||| S:328 E:332 ||| VBD
confirmed  ||| S:332 E:342 ||| VBN
by  ||| S:342 E:345 ||| IN
radiological ||| S:345 E:357 ||| NN
,  ||| S:357 E:359 ||| ,
laboratory ||| S:359 E:369 ||| NN
,  ||| S:369 E:371 ||| ,
and  ||| S:371 E:375 ||| CC
histological  ||| S:375 E:388 ||| JJ
investigations ||| S:388 E:402 ||| NNS
.  ||| S:402 E:404 ||| .
With  ||| S:404 E:409 ||| IN
a  ||| S:409 E:411 ||| DT
multidisciplinary  ||| S:411 E:429 ||| JJ
approach ||| S:429 E:437 ||| NN
,  ||| S:437 E:439 ||| ,
she  ||| S:439 E:443 ||| PRP
had  ||| S:443 E:447 ||| VBD
a  ||| S:447 E:449 ||| DT
successful  ||| S:449 E:460 ||| JJ
vaginal  ||| S:460 E:468 ||| JJ
delivery  ||| S:468 E:477 ||| NN
of  ||| S:477 E:480 ||| IN
a  ||| S:480 E:482 ||| DT
healthy  ||| S:482 E:490 ||| JJ
baby ||| S:490 E:494 ||| NN
.  ||| S:494 E:496 ||| .
She  ||| S:496 E:500 ||| PRP
was  ||| S:500 E:504 ||| VBD
treated  ||| S:504 E:512 ||| VBN
successfully  ||| S:512 E:525 ||| RB
by  ||| S:525 E:528 ||| IN
a  ||| S:528 E:530 ||| DT
combination  ||| S:530 E:542 ||| NN
of  ||| S:542 E:545 ||| IN
steroids ||| S:545 E:553 ||| NNS
,  ||| S:553 E:555 ||| ,
azathioprine  ||| S:555 E:568 ||| NN
and  ||| S:568 E:572 ||| CC
intravenous  ||| S:572 E:584 ||| JJ
immunoglobulin  ||| S:584 E:599 ||| NN
in  ||| S:599 E:602 ||| IN
the  ||| S:602 E:606 ||| DT
active  ||| S:606 E:613 ||| JJ
phase  ||| S:613 E:619 ||| NN
of  ||| S:619 E:622 ||| IN
disease  ||| S:622 E:630 ||| NN
for  ||| S:630 E:634 ||| IN
induction  ||| S:634 E:644 ||| NN
of  ||| S:644 E:647 ||| IN
remission  ||| S:647 E:657 ||| NN
and  ||| S:657 E:661 ||| CC
by  ||| S:661 E:664 ||| IN
azathioprine  ||| S:664 E:677 ||| NN
and  ||| S:677 E:681 ||| CC
steroids  ||| S:681 E:690 ||| NNS
for  ||| S:690 E:694 ||| IN
maintenance  ||| S:694 E:706 ||| NN
of  ||| S:706 E:709 ||| IN
remission ||| S:709 E:718 ||| NN
.  ||| S:718 E:720 ||| .
The  ||| S:720 E:724 ||| DT
significant  ||| S:724 E:736 ||| JJ
improvement  ||| S:736 E:748 ||| NN
in  ||| S:748 E:751 ||| IN
her  ||| S:751 E:755 ||| PRP$
symptoms  ||| S:755 E:764 ||| NNS
allowed  ||| S:764 E:772 ||| VBD
us  ||| S:772 E:775 ||| PRP
to  ||| S:775 E:778 ||| TO
continue  ||| S:778 E:787 ||| VB
her  ||| S:787 E:791 ||| PRP$
pregnancy  ||| S:791 E:801 ||| NN
to  ||| S:801 E:804 ||| TO
37  ||| S:804 E:807 ||| CD
weeks  ||| S:807 E:813 ||| NNS
when  ||| S:813 E:818 ||| WRB
delivery  ||| S:818 E:827 ||| NN
was  ||| S:827 E:831 ||| VBD
electively  ||| S:831 E:842 ||| JJ
induced ||| S:842 E:849 ||| NN
.  ||| S:849 E:851 ||| .
Transplacental  ||| S:851 E:866 ||| JJ
transmission  ||| S:866 E:879 ||| NN
of  ||| S:879 E:882 ||| IN
PR3-ANCA  ||| S:882 E:891 ||| NNP
occurred  ||| S:891 E:900 ||| VBD
but  ||| S:900 E:904 ||| CC
the  ||| S:904 E:908 ||| DT
neonate  ||| S:908 E:916 ||| NN
remained  ||| S:916 E:925 ||| VBD
well ||| S:925 E:929 ||| RB
.  ||| S:929 E:931 ||| .
This  ||| S:931 E:936 ||| DT
case  ||| S:936 E:941 ||| NN
of  ||| S:941 E:944 ||| IN
de  ||| S:944 E:947 ||| FW
novo  ||| S:947 E:952 ||| FW
WG  ||| S:952 E:955 ||| NNP
during  ||| S:955 E:962 ||| IN
pregnancy  ||| S:962 E:972 ||| NN
highlights  ||| S:972 E:983 ||| VBZ
the  ||| S:983 E:987 ||| DT
seriousness  ||| S:987 E:999 ||| NN
of  ||| S:999 E:1002 ||| IN
this  ||| S:1002 E:1007 ||| DT
disease  ||| S:1007 E:1015 ||| NN
and  ||| S:1015 E:1019 ||| CC
the  ||| S:1019 E:1023 ||| DT
challenge  ||| S:1023 E:1033 ||| NN
in  ||| S:1033 E:1036 ||| IN
management  ||| S:1036 E:1047 ||| NN
of  ||| S:1047 E:1050 ||| IN
such  ||| S:1050 E:1055 ||| JJ
patients ||| S:1055 E:1063 ||| NNS
.  ||| S:1063 E:1065 ||| .
